A Phase 3 extension study for pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) reached its primary completion on 2025-09-04. This long-term safety and efficacy study, identified as NCT03531255, enrolled 137 participants.
Background
Pegcetacoplan is being investigated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The study NCT03531255 is an open-label, non-randomized, multi-center extension study designed for subjects who have previously completed another pegcetacoplan study, focusing on long-term safety and efficacy.
Trial design
The Phase 3 extension study, NCT03531255, is an open-label, non-randomized, multi-center trial that enrolled 137 participants with paroxysmal nocturnal hemoglobinuria (PNH). The study is designed to assess the long-term safety and efficacy of pegcetacoplan in individuals who have previously participated in a pegcetacoplan study. The specific primary outcomes for this extension study were not detailed in the provided data.
What this means
The primary completion of this Phase 3 extension study signifies that the data collection for its primary endpoints has concluded as of 2025-09-04. As an open-label, non-randomized, multi-center study, its purpose is to gather long-term safety and efficacy data for pegcetacoplan in patients with PNH who have already been exposed to the drug in prior studies. While the specific primary outcomes were not detailed, the completion of this phase is a step towards understanding the sustained effects and safety profile of pegcetacoplan over an extended period. Clinicians and researchers will await the eventual publication of the study's findings to assess the long-term profile of pegcetacoplan for PNH.
Source
Information regarding the primary completion of this clinical trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT03531255, titled "Pegcetacoplan Long Term Safety and Efficacy Extension Study", was noted with a primary completion date of 2025-09-04 on clinicaltrials.gov.